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Dose tailoring of dabigatran
etexilate: obvious or excessive?
Jonathan Douxfils†, Franc¸ois Mullier & Jean-Michel Dogne
†University of Namur, Faculty of Medicine, Department of Pharmacy, Namur Research Institute for
LIfe Sciences (NARILIS), Namur Thrombosis and Hemostasis Center (NTHC), Namur, Belgium,
Europe
Introduction: Dabigatran etexilate is used for preventing blood clots and
tends to replace older anticoagulants in many of their indications. However,
the ‘one dose fits all’ policy is subject to criticism. Recent findings assert the
anxiety of the scientific community concerning the pharmacokinetic proper-
ties of dabigatran etexilate, that is, an important interindividual variability
including an important genetic variant with a significant dependence of the
renal function as route of elimination.
Areas covered: This meta-opinion provides an overview of the current knowl-
edge and evidence on the dose tailoring of dabigatran etexilate. It also dis-
cusses the remaining challenges to benefit from this perspective strategy to
enhance the benefit--risk balance of dabigatran etexilate. Data were searched
in the published literature and on regulatory agencies’ websites. Additionally,
unpublished data were searched and discussed.
Expert opinion: Causality between dabigatran exposure and bleeding risk is
now established and recommendations on how to best estimate the drug
exposure are published. Additionally, simulating studies revealed that a
dose adaptation based on dabigatran plasma concentration estimations could
improve the benefit--risk profile of the drug. This accumulating evidence sug-
gests that some patients under dabigatran etexilate may benefit from a tailor-
ing of the dose beyond the ones already proposed by the manufacturer.
Keywords: anticoagulant drugs, benefit--risk assessment, dabigatran etexilate, drug monitoring
Expert Opin. Drug Saf. [Early Online]
1. Introduction
In a recent viewpoint, Powell JR stressed out the interest of having the possibility to
tailor the dose of the different direct oral anticoagulants (DOACs) based on bio-
marker tests. The author suggested that ‘individualized DOAC dosing may benefit
to drugs with greater interpatient variability in pharmacokinetics or pharmacodynamics,
patients who do not have average characteristics, when other factors change or when
patients have multiple characteristics that could affect dosing’ [1]. To date, accumulat-
ing evidence point out the possibilities to improve the benefit--risk profile of these
compounds, especially for dabigatran etexilate (Pradaxa) -- a direct oral thrombin
inhibitor [1,2].
Since its launch, several cases of major bleeding including some with fatal out-
comes were reported post-marketing in the literature [3] or directly to the adverse
event databases worldwide. Interestingly, an evaluation of bleeding reports in the
FDA Adverse Event Reporting System during the first year of approval of dabiga-
tran etexilate suggests that fatal outcomes are higher in clinical practice than they
were in controlled clinical trials [4]. However, as underlined by Southworth et al.,
these case reports might have reflected a greater likelihood of reporting a bleeding
event in a patient receiving dabigatran etexilate than in one receiving warfarin; in
addition, life-threatening major bleedings are more likely to be reported than less
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serious cases, leading to some bias. The FDA thus compared
bleeding rates for dabigatran etexilate and warfarin using
insurance-claim data and administrative data from the FDA
Mini-Sentinel database [5]. They mentioned that results reflect
those of the large Phase III study in nonvalvular atrial fibrilla-
tion (NVAF), that is, that bleeding rates with dabigatran etex-
ilate did not appear to be higher than those with warfarin.
However, the lack of adjustment for confounding variables
and the lack of a detailed medical record review are some
weaknesses of this analysis that need to be highlighted. There-
fore, in order to address some limitations of the Mini-Sentinel
analysis, the FDA is currently conducting two protocol-based
assessments, using claims data from Mini-Sentinel and other
claims databases, in which adjustments will be performed
for confounding factors.
Out of the FDA investigation, a recent analysis of Medicare
beneficiaries found opposite results [6]. The authors reported
that in the real-world clinical practice, after adjusting for
patient clinical and demographic variables, dabigatran was
associated with a higher incidence of major bleeding regard-
less of the anatomical site [6]. Another investigation from a
large US database reported that, compared to warfarin, the
risk of major bleeding was not different among the two
groups, but a lower risk of hemorrhagic stroke and higher
risk of gastrointestinal bleeding was seen with dabigatran etex-
ilate. Importantly, although the risk of stroke is reduced with
dabigatran etexilate, it is still twice the one reported in the
RE-LY study, thus suggesting that real-life patients do not
benefit from dabigatran etexilate to the same extend than in
the RE-LY study [7]. In the meantime, other registries such
as the GARFIELD, the GLORIA-AF or the ORBIT-AF also
aim at expanding the real-life knowledge of antithrombotic
utilization in patients with AF [8-10]. These reports raised con-
cerns about the necessity of an individual monitoring to iden-
tify poor or high responders.
2. Current evidence
2.1 Rationale for dose tailoring
Dabigatran etexilate is an oral prodrug, rapidly converted by
esterases, notably liver esterase CES1, to dabigatran, a reversible
direct thrombin inhibitor. The pharmacokinetic properties of
the prodrug are characterized by a large interindividual vari-
ability in the bioavailability (3 -- 7%) [11]. Moreover, the active
metabolite dabigatran is mainly eliminated by the kidney. Its
clearance is therefore highly dependent on any fluctuation of
the renal function [12,13]. This led the regulatory authorities to
recommend an evaluation of the renal function by calculating
the creatinine clearance, using the Cockroft--Gault method,
prior to the initiation of the treatment.
Until recently, data on a possible correlation between the
drug exposure and clinical outcomes were lacking although
requested by experts in the field [14]. A reanalysis of the
RE-LY study by Reilly et al. showed that ischemic stroke
and bleeding outcomes were correlated with dabigatran
plasma concentrations [15]. It was revealed that both doses of
dabigatran etexilate tested in the RE-LY study were associated
with an impressive fivefold variation from 10th to the 90th
percentile of the dabigatran plasma range concentration.
Another recent study confirmed these results whether blood
samples were taken at trough or at peak [16]. As expected, renal
function was the predominant characteristic that determined
plasma concentration. In the study of Reilly et al. both safety
and efficacy outcomes were correlated with plasma concentra-
tions, whereas demographic characteristics (mainly age and
previous stroke) played the strongest role in determining risk
of clinical events. The authors concluded that for patients at
highest risk events, such as the very elderly and/or those
with poor renal function, a tailoring of the dose might
improve the benefit:risk ratio if they are at one or the other
extreme of the concentration range [15]. Additionally, in a sub-
group analysis of the same RE-LY study, genetic variants were
investigated to explain a part of the interindividual variabil-
ity [17]. Pare et al. showed that the rs2244613 single nucleo-
tide polymorphism (SNP) intronic to the esterase gene
CES1 was associated with a decreased trough concentrations
and a decreased risk of bleeding. Interestingly, this SNP was
present in 32.8% of the white European ancestry participants
of this study. No difference was found regarding the efficacy
of dabigatran etexilate. The authors conclude that routine
genotyping may enable clinicians to tailor the dose of dabiga-
tran etexilate for individual patients and thereby optimize the
balance between efficacy and safety [17]. These preliminary
pieces of evidence already suggest the importance of assessing
the individual response of such patients.
2.2 Position of the regulatory agencies
At the time of the submission of the marketing application for
the prevention of stroke and systemic embolism in patients
with NVAF, the FDA and the European Medicines Agency
Article highlights.
. Dabigatran etexilate is at least as efficacious as the
standard of care in the various indications.
. Dose tailoring was suggested based on several re-
analyses of the RE-LY study.
. Several groups of experts have already proposed
recommendations regarding when and how to perform
anticoagulant activity or concentration measurements.
. Recent findings strengthen the questioning of the
scientific community concerning the ‘one dose fits all’
policy.
. Simulating data suggests that a dose tailoring based on
early assessment of the response at the individual level
might improve the benefit--risk profile of dabigatran.
. Well-designed randomized controlled trial is required to
provide clear insights in this field.
This box summarizes key points contained in the article.
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made their decisions based on the results of the RE-LY trial,
which demonstrated the benefits and risks of unmonitored
dabigatran versus dose-adjusted warfarin.
However, the Clinical Pharmacology and Biopharmaceu-
tics Review(s) (NDA 22-512) of the FDA, first released in
September 2010 (i.e., before the marketing authorization in
US), already informed about the correlation between safety
and efficacy outcomes from the RE-LY study and dabigatran
plasma concentrations [13]. It is, indeed, clearly stated that
‘going from the 10th to 90th percentile of observed pre-dose dabi-
gatran concentrations (22.9 -- 238.3 ng/ml) in RE-LY, the prob-
ability of a major bleed within 1 year in a typical patient is
predicted to increase from 0.27% to 1.82%, while the probabil-
ity of an ischemic stroke within one year in a typical patient is
predicted to decrease from 1.05% to 0.52%’ [13]. Once imple-
mented together, these figures suggest that exceeding
200 ng/ml at Ctrough will increase the risk of bleeding without
supplemental protection against stroke. This is in line with
the data published by Reilly et al. In addition, in patients
with severe renal impairment, the FDA recommends to
reduce the dose to 75 mg twice daily (b.i.d.). Importantly,
this dose has not been tested in clinical trial in patients with
NVAF and this population was excluded from the RE-LY
study for safety reasons. Furthermore, based on simulations
studies provided in the Clinical Pharmacology and Biophar-
maceutics Review(s) (NDA 22-512), a dose of 75 mg/day
was recommended, whereas in the Summary Review and the
Labeling Information, the recommended dose is 75 mg
b.i.d. [13]. The rational behind the selected dose regimen is
clearly not provided, making a transparent assessment of the
efficacy of the 75 mg b.i.d. strategy in NVAF patients quite
difficult. The availability of an intermediate dose, that is,
the 110 mg b.i.d. dose regimen, would have provided an
option for high responders in whom the 75 mg b.i.d. dose
regimen cannot be recommended.
The EU-Summary of Product Characteristics (SmPC)
recommends the use of the 110 mg b.i.d. dose regimen in
patients aged > 80 years and those who receive concomitant
verapamil, a potent P-gp inhibitor. In patients aged between
75 and 80 years, with moderate renal impairment, with gastri-
tis, esophagitis or gastroesophageal reflux, and other patients
at risk of bleeding, the dose reduction should be selected
based on an individual assessment of the bleeding and throm-
botic risk [18]. This allows tailoring more precisely the dose of
dabigatran etexilate in frail patients. In addition, concerns had
been raised by the European Medicines Agency regarding the
large variability in plasma levels and bleeding risk. Specific
test thresholds associated with an increased risk of bleeding
at Ctrough were requested and are now provided in the EU-
SmPC. This document highlights that exceeding the 90th
percentile of dabigatran trough levels (i.e., 200 ng/ml) is con-
sidered to be associated with an increased risk of bleeding [18].
Moreover, in the assessment report of the Committee for
Medicinal Products for Human Use on the extension of the
indication to stroke prevention in NVAF (date release:
9 June 2011) [19], it was indicated that ‘anticoagulation mea-
surement has been requested at the time of the initial marketing
authorization application: [1] to better assess the drug during its
clinical development, [2] to provide tools to manage patients in
real-life in situations of increased bleeding risks, when event is
observed or when it is foreseen to occur (drug interactions, overdo-
ses, surgery, special populations)’.
Several groups of experts have already proposed recommen-
dations regarding when (Table 1) and how to perform antico-
agulant activity or concentration measurements [20-23]. The
activated partial thromboplastin time was initially proposed
to estimate the dabigatran’s intensity of anticoagulation but
presents an inter-reagent variability and does not correlate
well with dabigatran concentrations. Hence, a calibrated
dilute thrombin time, which has achieved the CE mark and
is commercially available in Europe, is proposed to accurately
estimate the plasma dabigatran concentration ranging from
50 to 500 ng/ml [19,24]. New methodologies even allow an
accurate measurement until < 10 ng/ml [25]. Unfortunately,
the FDA has not yet approved this test and mass spectrometry
thus remains the only method that can ensure accurate plasma
concentration measurements [24]. Importantly, the Commit-
tee for Medicinal Products for Human Use assessment report
mentioned that these tests can be used to decrease the dose in
case of increased exposure, but never to increase the dose in
case of lower exposure [19]. Moreover, the European Heart
Rhythm Association Practical Guide on the use of new oral
anticoagulants in patients with NVAF stressed out the fact
the quantitative assessment of the drug exposure may be
needed in emergency or in special clinical situations. They
also recommended dose adaptations when several interfering
factors are present in one individual but acknowledged that
information is not available yet for many potential interac-
tions with drug often used in AF patients [26]. This strongly
highlights that, in several cases not studied in clinical trials,
we cannot assert that these patients are not accumulating the
drug to a level associated with an increased risk of bleeding
and the current absence of commercially available antidote
precludes urgent reversal of the anticoagulant activity [26].
Inversely, we cannot warrant sufficient protection against
stroke or thromboembolism with interfering factors that
would enhance the clearance of the drug.
2.3 Lack of transparency
During US litigation proceedings, Boehringer Ingelheim was
asked to release its internal investigation on plasma level adjust-
ment [27]. Its assessment, based on the RE-LY sub-study, iden-
tified an expected therapeutic range for dabigatran in the
setting of NVAF. The company found that plasma concentra-
tion at Ctrough (i.e., 12 h after the last intake) between 90 and
140 ng/ml provided the best benefit:risk ratio between preven-
tion of stroke and occurrence of bleedings [27]. The design of
this simulation study was proposed as followed: after 1 week
of standard treatment with dabigatran etexilate 150 mg b.i.d.,
measurement of plasma drug level is performed at Ctrough.
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Three different algorithms were proposed based on doses avail-
able on the market. For patients with plasma concentrations
< 90 ng/ml, between 90 and 140 ng/ml and > 140 ng/ml,
the 150, 110 and 75 mg b.i.d. dose regimen were proposed,
respectively. The treatment period was ~ 20 months and the
simulation includes 5000 patients. The results showed that
29.9 and 25.5% of the patients would require the 110 and
75 mg b.i.d. dose regimen, respectively. This algorithm shifted
the exposure since the median Ctrough was reduced by 21%,
whereas the minimum exposure was unchanged and the 90th
percentile was significantly reduced [27].
Regarding the clinical outcome, they found that compared
with the reference treatment (i.e., 150 mg b.i.d.), the risk of
ischemic stroke and systemic thromboembolism events was
comparable (relative risk = 1.06; 90% CI = 0.76 -- 1.50),
whereas the risk of major bleeding is significantly reduced
(relative risk = 0.80; 90% CI = 0.66 -- 0.97). Compared to
warfarin (n = 4597), the risk of ischemic stroke and systemic
embolic events showed a trend for reduction (relative
risk = 0.80; 90% CI = 0.58 -- 1.11), whereas the risk of major
bleedings is significantly reduced (relative risk = 0.60; 90%
CI = 0.50 -- 0.72) [27]. These results clearly highlighted the
benefits in adjusting doses to optimize plasma level of
anticoagulation.
3. Conclusion
The recent findings strengthen the questioning of the scientific
community concerning the ‘one dose fits all’ policy for dabiga-
tran etexilate. The pharmacokinetic properties of dabigatran
etexilate were already highlighted and a proper drug monitor-
ing had been proposed in several cases. Causality between
dabigatran exposure and bleeding risk is now established; sim-
ulation data provide model to best manage patients and poten-
tially improve outcomes, and recommendations on how to
best perform estimations of drug exposure are published.
This accumulating evidence reveals that some patients under
dabigatran etexilate for chronic treatment may certainly benefit
from a tailoring of the dose probably beyond the ones already
stipulated in the different regulatory SmPCs. This is likely to
enhance the benefit--risk balance of dabigatran etexilate. Taken
together, this information suggests that, since the marketing
authorization, monitoring the plasma concentrations of dabi-
gatran in certain patients was recognized as a risk minimization
to improve the benefit:risk ratio of the product.
4. Expert opinion
This meta-opinion was focused on dabigatran etexilate since,
to date, this agent is the one for which the most data are avail-
able. However, the rationale can easily be expanded to other
DOACs. The debate concerning the monitoring of these
drugs is not new, with supporters of the pros and cons
[28,29]. Indeed, several criteria should be taken into consider-
ation when considering a proper drug monitoring: a high
i) intra- and ii) inter-individual variability in drug level,
both justifying identification of the optimal dose for each
patient at the start of treatment; iii) a low variability and
good reproducibility in the assay method; iv) a correlation
between drug level and clinical event; and v) the demonstra-
tion of the value of the therapeutic drug monitoring [29].
Concerning dabigatran etexilate, the intra- and inter-
individual variability in drug levels has been demonstrated
with these molecules while techniques to ensure plasmatic
measurements are now commercially available, at least in
Europe. Results from the RE-LY study indicate a correlation
between dabigatran exposure and bleedings and thus, the only
remaining issue consists on the demonstration of the benefit
of therapeutic drug monitoring. To our knowledge, no supple-
mental post-authorization efficacy and safety trials directly
comparing laboratory based dose-adjusted versus unmonitored
dabigatran etexilate therapy in NVAF population have been
requested/launched. Some investigations had been performed
in order to identify poor and high responders among typical
AF population [15,16]. Unfortunately, these analyses suffered
from several limitations [30,31]. Indeed, the monitoring of these
patients should take into account the rapid clearance of this
drug (i.e., half-life of ~ 13 h), depending on the renal func-
tion [11,18] and therefore, strict protocols are needed to avoid
biased results. In addition, in each of these ‘diagnostic’ studies,
clinical outcome must be collected and correlated with the
pharmacokinetic profile of the patient. There is, to date, no
clear consensus regarding when to perform such measurement
and when is the best time for sampling. However, sample taken
at trough steady state seem to be the appropriate choice to
correctly reflect the response at the individual level since the
trough value can be easily captured and also because harmful
threshold are provided for this sampling period.
Thus, a well-designed study is still needed to provide strong
recommendations in this field. However, if such a study is
envisaged, power calculations are necessary in order to accu-
rately assess the benefit of this approach. Simulation data
already suggested that compared to the reference treatment
(i.e., 150 mg b.i.d. in NVAF patients), titration of dabigatran
etexilate may reduce the rate of major bleedings from 4.38 to
Table 1. Summary of patients/situations that could
benefit from a monitoring of plasma concentrations
and/or a dose tailoring.
Bleeding or recurrence of thrombosis
Before an invasive procedure (elective or urgent surgery)
In patients with potential drug interactions that affect the
pharmacokinetics of dabigatran etexilate such as P-gp inhibitors
or inducers
In patients with genetic mutations (i.e., rs2244613 minor allele
carriers)
In patients with extreme body weight (< 50 or > 110 kg)
In elderly patients (> 75 years of age)
In case of accumulating interfering factors
J. Douxfils et al.























































3.49% (absolute event rate -- not annualized) [27]. Allowing an
a error of 5% and a statistical power of 80%, it will be needed
to include nearly 6000 patients in each group to see a statisti-
cal difference between these two types of intervention. The
major concern is that, without the input of the different reg-
ulatory authorities, it is unlikely that the drug company will
move into this direction and sponsor this investigation.
Pending the establishment of such researches, testing
should be envisaged in each patient in whom the therapeutic
response is not optimal or in which the establishment of the
intensity of anticoagulation is primordial for safety issue, as
summarized in Table 1. Repeated measures can be proposed
each time a new interfering factor is identified to ensure an
accurate response.
Testing should also be proposed with the other DOACs.
Indeed, a similar association between plasma concentrations
and clinical outcomes has been identified with edoxaban, a
direct factor Xa inhibitor [32]. For rivaroxaban and apixaban,
data are still lacking even if the FDA Clinical Pharmacology
and Biopharmaceutics Reviews of these molecules clearly sug-
gest an association between drug exposure and safety out-
comes [33,34]. However and importantly, factors other than
the plasma concentration could also affect the benefit--risk
profile of these drugs and the therapeutic range would proba-
bly not be the same for each category of patients. Namely, in
the ENGAGE AF-TIMI 48 trial, comparing edoxaban with
warfarin for stroke prevention in patients with NVAF,
patients who met the criteria for a dose reduction have higher
bleeding rates compared to those in whom the dose was not
reduced, despite lower edoxaban concentration at trough [32].
In conclusion, we are convinced that blood coagulation
testing will improve the benefit--risk profile of dabigatran
etexilate and probably other DOACs by identifying poor
and high responders. Further investigations based on the com-
ments raised through this meta-opinion are still required in
order to improve the efficacy and safety of the DOACs.
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